Press Release
Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders
NEWTON, Mass.--(BUSINESS WIRE)--May. 22, 2012-- Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 10:00 A.M. Eastern Time on Thursday, May 24, 2012, to provide an update following the Company’s Annual Meeting of Shareholders. Additionally, Peter Traber, MD, President, CEO and CMO of Galectin Therapeutics, will update the investment community on the Company’s pipeline of galectin inhibitor compounds in liver fibrosis and cancer.
The conference call and presentation will be webcast live over the internet and can be accessed by logging on to the Galectin Therapeutics website at www.galectintherapeutics.com. The call can also be accessed by dialing (866) 804-6929 (within the United States) or (857) 350-1675 (outside the United States). The passcode for participants is 46228838. Please log in approximately 10 minutes before the event to ensure a timely connection.
A replay of the call will be available after the live call concludes through June 7, 2012. To access the replay, dial (888) 286-8010 (within the United States) or (617) 801-6888 (outside the United States). The passcode is 58856118. The webcast will also be archived on the Company's website.
About Galectin Therapeutics
Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at http://www.galectintherapeutics.com.
Forward Looking Statements
This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.
Source: Galectin Therapeutics
Galectin Therapeutics Inc.
Maureen Foley, 617-559-0033
Chief Operating Officer